Today, the COB, CEO & Pres of Soligenix (NASDAQ: SNGX), Christopher Schaber, bought shares of SNGX for $4,977.
Following this transaction Christopher Schaber’s holding in the company was increased by 14.07% to a total of $42.65K.
See today’s analyst top recommended stocks >>
Based on Soligenix’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $1.73 million and GAAP net loss of $1.56 million. In comparison, last year the company earned revenue of $991K and had a GAAP net loss of $2.31 million. Currently, Soligenix has an average volume of 1.2M.
Starting in March 2018, SNGX received 6 Buy ratings in a row. Four different firms, including Maxim Group and National Securities Corp, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the BioTherapeutics, and Vaccines/BioDefense segments.
